Razionale scientifico

Pituitary adenomas/PitNET represents a complex disease, with a wide spectrum of clinical manifestations, from small benign lesions to aggressive PitNET, according to the ability of secreting different hormones or pro-hormones or of invading the neighbouring anatomical structures and to treatment resistance. Macroadenomas can cause mass effect, consisting of visual field defects, headache or hypopituitarism. People with hypopituitarism due to pituitary adenomas have an approximately 2-fold increase in all-cause mortality compared with the general population. Some syndromes of pituitary hormone excess are also associated with excess all-cause mortality. Acromegaly was associated with a 2-fold increase in all-cause mortality rate in studies published before 2008, but not in more recently published studies or in the subgroups of patients who achieved biochemical control of the disease. Cushing disease has been associated with a 3-fold increase in all-cause mortality rate. Aggressive PitNETs (APTs) are a small subset, around 10% of all PitNETs, defined as tumours which are radiologically invasive with unusually rapid tumour growth or clinically relevant tumour growth despite optimal standard therapies. Pituitary carcinomas (PCs) specifically denote APTs that have metastasised (craniospinal or systemic) and comprise up to 0.4% of all PitNETs. Current guidelines for the management of APTs and PCs recommend treatment with surgery, radiotherapy and temozolomide; however by definition these tumours progress despite these therapies and treatment options beyond current recommendations are experimental. In this field, precision medicine management is a rapidly expanding area that enables delivery of molecular based personalised therapies, and this approach may improve outcomes for patients with PitNET. In the recent years, a wide number of research investigated the genetic, molecular and biological features of PitNETs, in order to predict the clinical behaviour of these neoplasia and to personalize the treatments. The current event has the aim of updating participants on the latest biological, genetic and clinical acquisitions on PitNET and on their impact in the management of PitNET affected patients according to the new knowledge, that requires a close clinical collaboration between neuroendocrinologist, ophthalmologist, pathologists, neurosurgeons, radiotherapist and nuclear medicine physician. The meeting is part of the teaching activities of the Master Degree in Diagnosis and Treatment of pituitary disease - Faculty of Medicine, Universita' Cattolica del Sacro Cuore, Rome.

Luogo

Hotel Donna Camilla Savelli
Via Garibaldi 27, Roma (RM)

Programma

Responsabili del corso

• Antonio Bianchi

  Responsabile scientifico

  Specializzazione: Patologie ipotalamo-ipofisarie

  Struttura: Fondazione Policlinico Universitario A. Gemelli - IRCCS Roma

  Ruolo: Dirigente medico I livello U.O.S. di Patologie Ipotalamo-ipofisarie

• Laura De Marinis

  Responsabile scientifico

  Specializzazione: Patologie ipotalamo-ipofisarie

  Struttura: Universita' Cattolica del Sacro Cuore

  Ruolo: Coordinatore Scientifico Master Universitario II Livello in diagnosi e terapia delle patologie ipotalamo-ipofisarie

Relatori e docenti

• Gianluca Aimaretti

  Moderatore

  Specializzazione: Endocrinologia

  Struttura: Universita' del Piemonte Orientale

  Ruolo: Professore Ordinario di Endocrinologia

• Mattia Barbot

  Relatore

  Specializzazione: Endocrinologia

  Struttura: Universita' degli Studi di Padova

  Ruolo: Ricercatore strutturato

• Carmelo Caldarella

  Relatore

  Specializzazione: Medicina Nucleare

  Struttura: Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma

  Ruolo: Dirigente Medico, Centro PET TC

• Salvatore Cannavo

  Moderatore

  Specializzazione: Endocrinologia

  Struttura: Universita' degli Studi di Messina

  Ruolo: Professore Ordinario di Endocrinologia

• Ettore Domenico Capoluongo

  Moderatore

  Specializzazione: Biochimica clinica e Biologia molecolare clinica

  Struttura: Universita' degli studi di Napoli Federico II

  Ruolo: Ordinario di Biochimica clinica e Biologia molecolare clinica

Con il contributo non vincolante di

Domande frequenti